Poor
Not Aligned
Patient Risk:
Low
Summary
All extracted claims are unsupported by the provided FDA label excerpts. The label content shown discusses adverse reactions such as hyperglycemia but does not mention sweet cravings, appetite/weight outcomes, fasting glucose/HbA1c effects, or comparative statements across statins.
Category Scores
Accurate Statements
Unsupported Statements
Patients on atorvastatin (Lipitor) rarely report new or intensified cravings for sweets in clinical studies.
The provided label excerpts (6.1) do not mention cravings/appetite or sweet cravings.
In post-marketing surveillance, patients on atorvastatin (Lipitor) rarely report new or intensified cravings for sweets.
The provided label excerpts (6.2) do not mention cravings/appetite or sweet cravings.
Any perceived change in cravings while taking atorvastatin (Lipitor) usually relates more to lifestyle factors, other medications, or metabolic shifts than to the statin itself.
The provided label excerpts do not address cravings or attribution/causality for craving changes.
Atorvastatin can modestly raise fasting glucose in some users.
The provided excerpts mention hyperglycemia as an adverse reaction but do not state effects on fasting glucose.
Atorvastatin can modestly raise HbA1c in some users.
HbA1c is not mentioned in the provided label excerpts.
The effect of atorvastatin on fasting glucose and HbA1c is dose-dependent.
The provided label excerpts do not describe dose-dependent effects on fasting glucose or HbA1c.
The effect of atorvastatin on fasting glucose and HbA1c is more noticeable in people already at risk for diabetes.
The provided label excerpts do not describe differential effects based on baseline diabetes risk.
Atorvastatin does not directly trigger sugar cravings.
The provided label excerpts do not discuss sugar cravings or whether atorvastatin directly triggers them.
Large trials show no consistent impact of atorvastatin on appetite.
The provided label excerpts do not mention appetite outcomes from clinical trials.
Large trials show no consistent impact of atorvastatin on body weight.
The provided label excerpts do not mention body weight outcomes from clinical trials.
Average weight change across studies of atorvastatin is near zero.
No average weight change data across studies is present in the provided label excerpts.
Individual reports of weight change with atorvastatin vary.
The provided label excerpts do not address variability in weight change reports.
Similar patterns appear with most statins regarding cravings for sweets.
The provided label excerpts do not provide comparative conclusions across statins regarding sweet cravings.
None of the statins stand out for increasing sweet cravings.
The provided label excerpts do not discuss sweet cravings across statins or provide comparative conclusions.
Differences among statins relate mainly to potency, dosing frequency, and side-effect profiles rather than appetite changes.
The provided label excerpts do not discuss statin-to-statin differences in relation to appetite changes.
Contradictions
Important Omissions
Any label-supported information about glucose monitoring specifics (fasting glucose/HbA1c) and related cautions/management, if present in the full label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims are primarily about cravings/appetite/weight and specific glucose metrics (fasting glucose/HbA1c). While not label-supported, they do not directly provide contraindications, dosing instructions, or false administration directions within the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
All evaluated claims are unsupported by the provided FDA label excerpts; multiple claims introduce specific outcomes (sweet cravings, appetite/body weight effects, fasting glucose/HbA1c dose- and risk-modifying effects) that are not addressed in the supplied label text.
Suggested Improvement
Remove or revise claims so they are explicitly supported by the provided label sections; limit statements to adverse-reaction language present in the excerpts (e.g., hyperglycemia as an adverse reaction category) unless additional on-label label text is supplied for appetite/craving and fasting glucose/HbA1c endpoints.